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Abstract 35 
Gaucher disease (GD) and primary myelofibrosis (PMF) share similar clinical and laboratory 36 
features such as cytopenia, hepatosplenomegaly and marrow fibrosis, resulting often in a 37 
misdiagnosis. We report here the case of a young woman with with hepatosplenomegaly, leukopenia 38 
and thrombocytopenia. Based on bone marrow (BM) findings and on liver biopsy showing 39 
extramedullary hematopoiesis, an initial diagnosis of PMF was formulated. The patient refused stem 40 
cell transplantation from an HLA-identical sibling. Low-dose melphalan was given without any 41 
improvement. Two years later, a BM evaluation showed Gaucher cells.  42 
Low glucocerebrosidase and high chitotriosidase levels were indicative for GD. Molecular analysis 43 
revealed N370S/complex I mutations. Enzyme replacement therapy (ERT) with imiglucerase was 44 
started resulting in clinical and hematological improvements. Due to an unexpected and persistent 45 
organomegaly, PMF combined with GD were suspected. JAK2V617F, JAK2 exon 12, MPL, 46 
calreticulin (CARL) and exon 9 mutations were negative and BM examination showed no marrow 47 
fibrosis. PMF combined with GD were excluded. Twenty years after starting ERT, the peripheral 48 
cell count and liver size were normal, whereas a mild splenomegaly persisted. In order to avoid 49 
future misdiagnosis, a diagnostic algorithm for patients with hepatosplenomegaly combined with 50 
cytopenia is suggested. 51 
 52 
Introduction 53 
Gaucher disease (GD), a rare autosomal recessive disorder, and primary myelofibrosis (PMF), a rare 54 
clonal myeloprolipherative neoplasm (MPN), may present similar features such as 55 
thrombocytopenia, anemia, leukopenia, splenomegaly and marrow fibrosis, resulting in a diagnostic 56 
challenge. 57 
 58 
Case Report 59 
In November 1994, a 32 year-old woman, with a clinical history of non-traumatic bone fractures 60 
(femur and tibia) at the age of 15 years with unknown causes, was referred to our center due to 61 
hepatosplenomegaly, leukopenia and thrombocytopenia. The patient had been asymptomatic until 62 
1990 when hepatosplenomegaly was found during her fourth pregnancy (she had previously had 63 
three spontaneous abortions). At that time, the peripheral blood (PB) cell count, serum proteins and 64 
albumin, kidney and liver function were in the normal range, except for mild liver enzyme 65 
abnormalities and thrombocytopenia. A liver biopsy, performed during the caesarian section, 66 
revealed extramedullary hematopoiesis. Despite this finding, the patient was referred to our Center 67 
only in 1994, with a suspect diagnosis of PMF. On admission, clinical examinations revealed 68 
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hepatomegaly and palpable splenomegaly; the full blood count showed thrombocytopenia (platelets 69 
78x109/L) and leukopenia (leukocytes 3.2x109/L with a normal differential count) with a 70 
hemoglobin (Hb) level of 11.1 g/dL; the serum ferritin level was 566 μg/L. An abdominal 71 
ultrasonography confirmed the hepatomegaly (Ø 146 mm) and splenomegaly (Ø 246x112x104 mm). 72 
Cytogenetic analysis revealed an inherited translocation t(6,13) without clinical significance. A BM 73 
biopsy showed a decreased cellularity, normal megakaryocytic proliferation with atypia (lobulated 74 
and nacked nuclei) and a significant increase of reticulin fibers and collagen deposition. A diagnosis 75 
of PMF was made. Given the young age and the availability of an HLA-matched sibling, a stem cell 76 
transplantation was considered but the patient refused. Low-dose melphalan was then given. Two 77 
years after starting treatment, the persisting thrombocytopenia, leukopenia and hepatosplenomegaly 78 
led us to perform a BM revaluation. Surprisingly, hystiocyte clusters CD68R+ (PAS/PAS-D+) 79 
suggestive of Gaucher cells and an increased marrow cellularity, normal granulopoiesis, 80 
erythropoietic and megakaryocytic dysplasia, significant reticulin and collagen fibrosis were found. 81 
Low-dose melphalan was stopped. Low glucocerebrosidase activity and high value of chitotriosidase 82 
were suggestive for GD. Molecular analysis revealed the N370S/complex I mutations, allowing a 83 
diagnosis of non-neuropathic type I GD. A further comprehensive assessment of all potentially 84 
affected organ systems was performed. A full blood count was as follows: platelets 71 x109/L, 85 
leukocytes 3.2x109/L, Hb 10.5 g/dL and ultrasonography confirmed increased hepatomegaly and 86 
unchanged splenomegaly. Skeletal evaluation (X-rays and dexa mineralometry) excluded bone 87 
involvement. In June 1997, enzyme replacement therapy (ERT) with imiglucerase at a monthly dose 88 
of 30 U/kg was started. One year later, due to persistent pancytopenia and unchanged 89 
hepatosplenomegaly, the ERT dose was increased to 60 U/kg/monthly. Platelets and leukocytes 90 
count, as well as the hemoglobin level, reached the normal range 6 years after starting treatment. 91 
Subsequently, a persistent hepatosplenomegaly suggested a combined PMF and GD. Human 92 
androgen receptor assay (HUMARA) PCR analysis [1] showed a polyclonal hematopoiesis. In 93 
February 2008, the JAK2V617F, JAK2 exon 12 and MPL mutations were analyzed in PB cells as 94 
previously described [2]. No mutations of the investigated genes were found. The patient continued 95 
ERT at a dose of 60 U/Kg/monthly. In 2013, calreticulin (CARL) exon 9 analysis was carried out 96 
without any evidence of mutations [3, 4]. At this time, the PB values were normal, whereas 97 
splenomegaly and mild hepatomegaly persisted. An additional BM biopsy was done. The medullary 98 
framework was characterized by a normal hematopoiesis, the presence of scattered Gaucher cells 99 
and absence of fibrosis. A diagnosis of PMF was excluded. The patient continued ERT at the same 100 
dose obtaining a progressive reduction of the hepatosplenomegaly. At the last follow up in 2017, 101 
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twenty years after starting treatment, the PB cell count was normal; ultrasonography and MRI 102 
revealed a mild splenomegaly (Ø 140x100x90 mm) and a normal liver size. 103 
 104 
Discussion 105 
GD and PMF share many clinical and laboratory features to such an extent that GD can be easily 106 
missed as a possible diagnosis. In order to diagnose PMF, a BM biopsy is essential. However, a BM 107 
biopsy is also indicated in GD when the differential diagnosis with a hematologic disease is 108 
necessary. In the case presented, the first BM biopsy confirmed the suspect of PMF because of a 109 
stricking marrow framework of myelofibrosis without Gaucher cells. Instead, the second BM biopsy 110 
showing the presence of both fibrosis and lipid-storage macrophages suggested the diagnosis of GD 111 
that was confirmed by assessing the glucocerebrosidase activity and by molecular analysis. In both 112 
PMF and GD there is an activation of pro-inflammatory cytokine pathways that could have an 113 
important role in the modification of the bone marrow microenvironment leading to the development 114 
of marrow fibrosis. Genetic and epigenetic abnormalities, that can be found in PMF, play a role in 115 
the defective clonal hematopoietic stem cell proliferation, with the release of several cytokines in the 116 
marrow microenvironment. While, in GD a malfunction of the lipid-storage macrophages, namely 117 
Gaucher cells, induces an increased expression of pro-inflammatory cytokines leading to a marrow 118 
fibrosis [5]. The framework from the first biopsy was due to the activation of many pro-119 
inflammatory cytokines by unidentified Gaucher cells, while BM framework of the last biopsy was 120 
the result of the ERT activity on the reticulinic and collagen fibers.  121 
Assessment of somatic acquired JAK2V617F, JAK2 exon 12, MPL and CALR gene mutations in the 122 
PB has recently become a mandatory diagnostic tool in MPN, including PMF, as the presence of one 123 
of these mutations is a major criterion for PMF according to the 2016 WHO classification [6]. In 124 
conclusion, the diagnosis of GD should be considered in the presence of a long-lasting splenomegaly 125 
and hepatomegaly combined with cytopenia. In order to avoid future misdiagnosis, the use of a 126 
diagnostic algorithm for patients with combined hepatosplenomegaly and cytopenia is recommended 127 
(Figure 1). 128 
129 
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Figure 1. A proposed diagnostic algorithm for patients with long-lasting hepatosplenomegaly and 148 
cytopenia.  149 
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JAK2: Janus Kinase2; CARL: calreticulin; MPL: myeloproliferative leukemia oncogene; PMF: 152 
primary myelofibrosis. 153 
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